|
Genomic profile at diagnosis by targeted high throughput sequencing, and real-world clinical outcomes in patients diagnosed with acute myeloid leukemia at a tertiary care cancer center. |
|
Vivek Sulekha Radhakrishnan |
Stock and Other Ownership Interests - Cipla; Dr. Reddy's Laboratories; NATCO Pharma |
Consulting or Advisory Role - Cipla (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); NATCO Pharma (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Dr. Reddy's Laboratories (Inst); Pfizer (Inst) |
(OPTIONAL) Uncompensated Relationships - Aurigene Discovery Technologies (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
Research Funding - NATCO Pharma (Inst) |